Blunt Newswire Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America SAN DIEGO, April 18, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a.. 18 Apr